Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Long-Term Response Durability of Infliximab for Pediatric Inflammatory Bowel Disease in Japan: A Single Center Experience
Publication Year: 2025 Source: Pediatr Gastroenterol Hepatol Nutr PMID: 40396153 DOI: 10.5223/pghn.2025.28.3.166
PURPOSE: The long-term efficacy and safety of infliximab (IFX) in Japanese children with inflammatory bowel disease (IBD) remain unclear. This study aimed to examine the long-term outcomes of IFX treatment in Japanese children with IBD. METHODS: We retrospectively recruited patients aged <16 years who were diagnosed with ulcerative colitis (UC) …
Transitioning Pediatric Patients with Inflammatory Bowel Disease: Key Considerations for Adult Gastroenterologists
Publication Year: 2025 Source: Pediatr Gastroenterol Hepatol Nutr PMID: 40396154 DOI: 10.5223/pghn.2025.28.3.141
No Abstract
Magnetic Resonance Enterography of Phlebosclerotic Colitis: A Case Report
Publication Year: 2025 Source: Curr Med Imaging PMID: 40396322 DOI: 10.2174/0115734056382571250509114555
BACKGROUND: Phlebosclerotic colitis is a rare type of chronic ischemic colitis, with most documented cases occurring in Asians. Plain-film and computed tomography findings of pericolonic vascular calcifications are diagnostic. However, Magnetic Resonance Enterography (MRE) findings of phlebosclerotic colitis have not yet been reported, and its diagnosis might be overlooked without …
The 'totality of evidence' and 'extrapolation' of SB17, a ustekinumab biosimilar
Publication Year: 2025 Source: Expert Opin Biol Ther PMID: 40396611
INTRODUCTION: SB17 is a ustekinumab (UST) biosimilar targeting interleukin-12/23 for treating immune-mediated inflammatory diseases (IMIDs). The development of UST biosimilars like SB17 may help address the high cost of innovator biologics, offering affordable alternatives without compromising efficacy or safety. AREAS COVERED: This review encompasses the totality of evidence supporting SB17's …
Discovery of a Novel Serine-Targeting Covalent Inhibitor against HCES2A for Treating Drug-induced Diarrhea and Ulcerative Colitis
Publication Year: 2025 Source: J Med Chem PMID: 40396776
Mammalian carboxylesterases play an important role in the hydrolysis of both endogenous substrates and xenobiotics bearing ester or amide bond(s). We previously reported that bysspectin A and its derivative LC-20W were potent reversible hCES2A inhibitors. Here, a series of bysspectin A derivatives were designed and synthesized using LC-20W as the …
Cerebral Infarction with Cerebral Thrombosis in Crohn's Disease: A Case Report
Publication Year: 2025 Source: Acta Neurol Taiwan PMID: 40396799
We describe a case report of a young male with Crohn's disease who presented with cerebral infarction and cerebral thrombosis. The patient's Crohn's disease had been in remission for 7 years without any recurrent strokes during this period. Our case highlights the need to consider inflammatory bowel disease as a …
Exploring the therapeutic potential of annexin A1-derived peptide Ac(2-26) in modulating NLRP3 inflammasome activation in Crohn's disease
Publication Year: 2025 Source: Mol Cell Biochem PMID: 40397291 DOI: 10.1007/s11010-025-05311-1
Inflammatory bowel disease (IBD) remains a complex and multifaceted condition, with its management dependent on a thorough understanding of its underlying mechanisms. While the ANXA1-FPR axis is implicated in the pathogenesis of IBD, its relationship with the NLRP3 inflammasome in this context has not been established. Thus, this study aimed …
Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn's Disease Activity: A Prospective Cross-Sectional Study
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 40397476
BACKGROUND: The goal of treatment for Crohn's disease (CD) is to achieve mucosal or transmural healing, and biomarker measurements are useful in monitoring disease activity and guiding treatment. This study aimed to investigate the utility of a new urinary biomarker, prostaglandin E-major urinary metabolite (PGE-MUM), in assessing CD activity. METHODS: …
Unravelling the Relationship Between Obesity and Inflammatory Bowel Disease
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 40397482 DOI: 10.1093/ibd/izaf098
Mirroring the global obesity epidemic, obesity rates in inflammatory bowel disease (IBD) patients is rising. Several epidemiological studies propose that 15%-40% of adult patients with IBD are obese, and an additional 25%-40% fall into the overweight category. This article examines the pathophysiologic relationship between obesity and IBD concerning the role …
Recombination of miR-146b by Lactococcus lactis for Remolding Macrophages and the Microbiome in the Treatment of Murine Colitis
Publication Year: 2025 Source: J Agric Food Chem PMID: 40397547 DOI: 10.1021/acs.jafc.4c11183
MicroRNA 146b (miR-146b) mitigates the progression of inflammatory bowel disease (IBD) by reprogramming macrophage polarization through the induction of interleukin-10 (IL-10), thereby eliciting an anti-inflammatory response, but its application is currently hindered by the lack of safe delivery systems that allow sustained miR-146b expression. Inspired by the probiotic Lactococcus lactis, …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide